Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
FEATURED:
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
Fitzsimons Innovation Community is where innovators come to turn ideas into business.
A regular feature of a Fitzsimons Innovation Community visionary.
Our year in innovation.
Find out what’s happening on campus and across the industry.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Fitzsimons Innovation Community President & CEO Kelly Brough was recently featured on Visit Aurora, Colorado's The Gateway to the Rockies Podcast where she shared the bold vision behind the newly approved master plan and how the Fitzsimons campus is transforming into Aurora’s first true urban district. From cutting-edge research that's reshaping patient care to green spaces, housing innovation, public art, and world-class labs, she dives into how Fitzsimons is redefining what it means to live, work, and discover in Colorado.
CU Anschutz researchers help lead the largest U.S. randomized trial highlighting ketamine’s cardiovascular risks while guiding emergency and critical care practice.
A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years.
A first-of-its-kind combination therapy could make treatment more effective by attacking hard-to-treat cancer from two angles.
The Global Business Development division of the Colorado Office of Economic Development and International Trade (OEDIT) announced that 17 Colorado companies and eight researchers have been awarded Proof of Concept and Early-Stage Capital and Retention grants through OEDIT’s Advanced Industries Accelerator Program. Congratulations to the Fitzsimons Innovation Community Early-Stage Capital and Retention Grant Recipients: Onconaut Therapeutics, Inc., Vega Surgical, Inc., and Vona Oncology LLC.
UCHealth said it's the first in Colorado to offer a kind of mammogram that could be a game changer when it comes to detecting breast cancer. Dr. Elizabeth Vorhis, a breast radiologist said she uses an IV contrast during a mammogram. It's the same kind of process if you go to the emergency room and get a stomach or chest CT scan.
Colorado BioScience Association (CBSA) announced the winners of its 22nd Annual Awards Celebration, recognizing the people and organizations advancing Colorado’s position as a leading hub for health innovation. The awards spotlight leaders whose work accelerates breakthrough discoveries and delivers impact for patients in Colorado and around the world. Dr. Katherine Goodman, Associate Professor at the University of Colorado Denver | Anschutz, received the Educator of the Year Award for her outstanding contributions to shaping Colorado’s future life sciences workforce. EnteroTrack and RheumaGen were honored as Rising Star of the Year finalists.
Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.
Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.
Earlier this year, Kate Goes became the first patient in North America to use FDA-approved adaptive deep brain stimulation (DBS) technology for Parkinson’s. UCHealth Ph.D. clinical neuropsychologist John Thompson helped make the pathbreaking innovation possible.
The University of Colorado system generated $12.2 billion in economic impact across Colorado last year, highlighting CU’s growing role in the state’s economy through education, research, innovation and health care, according to a new economic study. This is growth of more than half a billion dollars over 2024.
Colorado Real Estate Journal's latest Health Care and Life Sciences Quarterly features an article from Dr. Terry Fry, Executive Director of the Gates Institute at University of Colorado Anschutz, about how the proximity between academia, biomanufacturing, and industry collaboration at Fitzsimons accelerates the development of life-changing cell and gene therapies.
Fitzsimons Innovation Community
